Revelation Biosciences (NASDAQ:REVB) Issues Quarterly Earnings Results, Misses Estimates By $0.24 EPS

Posted by Patrick Bannon on Feb 26th, 2026

Revelation Biosciences (NASDAQ:REVB – Get Free Report) released its earnings results on Thursday. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.24), FiscalAI reports.

Revelation Biosciences Price Performance

Shares of NASDAQ:REVB opened at $1.32 on Friday. The business has a 50-day moving average of $2.53 and a two-hundred day moving average of $4.92. The firm has a market capitalization of $9.11 million, a PE ratio of -0.02 and a beta of -0.11. Revelation Biosciences has a 12 month low of $1.29 and a 12 month high of $46.31.

Institutional Trading of Revelation Biosciences

A hedge fund recently bought a new stake in Revelation Biosciences stock. Geode Capital Management LLC acquired a new position in shares of Revelation Biosciences, Inc. (NASDAQ:REVB – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 34,019 shares of the company’s stock, valued at approximately $27,000. Geode Capital Management LLC owned approximately 2.15% of Revelation Biosciences at the end of the most recent reporting period. 12.80% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of Revelation Biosciences in a report on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

View Our Latest Stock Report on Revelation Biosciences

About Revelation Biosciences

(Get Free Report)

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.